The U.S. Supreme Court has stepped in, for now, to keep the abortion pill mifepristone accessible via mail. Justice Samuel Alito, acting on behalf of the court, issued an order on Monday, May 4, 2026, temporarily halting a previous appellate court decision that sought to restrict the drug's distribution. This move, at least for the next few days, preserves the current access for patients who rely on mail-order services for the medication. The immediate impact is the reinstatement of nationwide access to mifepristone, preventing an abrupt shift in how the drug is dispensed.
A Temporary Pause in the Legal Scramble
The Supreme Court's intervention came swiftly after Danco Laboratories, the manufacturer of mifepristone, and GenBioPro, which produces a generic version, filed emergency appeals. Their requests aimed to block a ruling from the 5th U.S. Circuit Court of Appeals. This lower court had, on Friday, ordered a return to stricter dispensing requirements for mifepristone, specifically demanding in-person administration and blocking its delivery through the mail. Justice Alito's order grants a temporary reprieve, giving the Supreme Court more time to deliberate as the legal wrangling over the drug continues.
Read More: Supreme Court: Abortion Pill Mifepristone Still Available by Mail Until May 14
Louisiana's Challenge and the FDA's Role
The controversy centers on the Food and Drug Administration's (FDA) decision in 2023 to ease restrictions on mifepristone, allowing it to be prescribed via telehealth and dispensed through the mail. This regulatory shift prompted a legal challenge from Louisiana, with Attorney General Liz Murrill arguing that mailed delivery circumvents state abortion bans. The 5th Circuit Court of Appeals sided with Louisiana, stating the state was likely to succeed in its challenge, which led to the Friday ruling that the Supreme Court has now temporarily suspended.
Read More: Texas AG Sues Netflix for Spying on Children's Data
Wider Implications and the Drug's Usage
Mifepristone is a critical component in medication abortions, accounting for nearly two-thirds of all abortions performed in the United States. The legal battles surrounding its accessibility, particularly through mail-order channels, underscore its significance in the broader reproductive healthcare landscape, especially in the wake of the Supreme Court's 2022 decision overturning Roe v. Wade.
Timeline of the Interventions
Friday, May 1, 2026: A fifth U.S. circuit court of appeals issued a ruling demanding the revival of an in-person dispensing requirement for mifepristone, effectively blocking mail-order access.
Saturday, May 2, 2026: Danco Laboratories and GenBioPro filed emergency appeals with the U.S. Supreme Court.
Monday, May 4, 2026: Justice Samuel Alito, on behalf of the Supreme Court, signed an order temporarily pausing the appellate court's ruling and restoring mail-order access. Louisiana has until 5 p.m. ET on Thursday, May 7, 2026, to respond to the appeals. The Supreme Court has blocked the appeals court ruling until at least May 11, 2026, while legal briefs are filed.